Feature | December 26, 2013

IMV Market Report Shows Nuclear Medicine Providers are Consolidating as Procedure Volume Slows

nuclear imaging spect spect/ct IMV
December 26, 2013 — A report released by IMV Medical Information Division found that providers of nuclear medicine (NM) services are consolidating as procedure volume dropped in the subspecialty from 2008 to 2012. 
An estimated 14.5 million nuclear medicine patient studies were performed on 14,825 single-photon emission computed tomography (SPECT) or SPECT/CT in the United States in 2012. Compared with the 16 million patient studies performed in 2008, total nuclear medicine patient studies have decreased about 9 percent, for an average annual decline of 2.5 percent per year from 2008 to 2012. 
“We attribute this decline in NM patient studies to several factors, including the impact of precertification requirements from health insurance companies, reduced reimbursement and studies shifting to competing technologies, such as bone studies shifting to PET,” said Lorna Young, senior director of market research, IMV. 
IMV’s study also shows that physician practice locations (primarily cardiology practices) are feeling financial pressure due to reduced reimbursement from Medicare and third-party payors. When asked about the issues affecting their future outlook, both hospitals and non-hospitals responded that “reductions in Medicare and third-party reimbursements are causing NM revenue to decline” is their top-rated issue, but managers of physician practices are more likely to rate this as a top issue than are administrators of hospital nuclear medicine departments. 
Due to these pressures, the number of physician practices performing nuclear medicine studies has declined 6 percent over the past two years, and this decline is likely to continue. 
Respondents from physician office locations were asked if they were planning to pursue certain strategic actions over the next few years, including changing their practice ownership structure to include a joint venture with hospitals. Almost one-third of the respondents are either considering or planning such a change in their practice model. 
This in turn is impacting their purchase plans for nuclear medicine cameras. While 29 percent of the nuclear imaging sites in the survey are independent physician office locations, less than 10 percent of the sites planning camera purchases through 2015 will be physician offices. 
According to the report, while the nuclear medicine market is currently slowing down with the decline in patient studies and a reduction in the number of sites performing NM studies, there is a relatively large installed base of aging equipment. Of the sites that are planning to purchase NM cameras, almost 90 percent of the planned purchases will be for replacement units.
Based on market scenarios for unit sales from 2013 to 2017 provided in the report, IMV anticipates that the years 2015-2017 will be relatively active years for system replacements. One driver for replacement activity is the SPECT/CT camera, which will comprise at least 40 percent of the planned purchases for nuclear medicine cameras.
IMV’s 2013 Nuclear Medicine Market Outlook Report describes trends in nuclear medicine patient volume by study type, radiopharmaceutical and pharmacological stress agent utilization, SPECT versus SPECT/CT camera installed base and purchase plans, site operations characteristics and department managers' opinions about the factors affecting the future outlook for nuclear medicine.
In the report, IMV also provided market scenarios for nuclear medicine camera purchases from 2013 through 2017. Vendors covered in this report include Cardinal Health, Digirad, GE, Philips, Siemens, Spectrum Dynamics and Triad. 
Additional highlights include:
  • A larger 80 percent proportion of the NM studies conducted in nonhospital locations are cardiovascular studies, compared with 46 percent of those conducted in hospitals. Hospitals are more likely to be conducting other procedure types, including bone scans, liver/hepatobiliary, renal, respiratory, infection/abscess and tumor localization studies. 
  • An estimated 8 million myocardial ischemia perfusion studies were performed in 2012, of which 58 percent used pharmacological stress agents, either alone or with exercise. 
  • Just over 25 percent of sites indicated providing neurology applications, and this may grow to more than one-third by 2016.
IMV's 2013 Nuclear Medicine Market Outlook Report is based on the responses to an IMV-hosted online survey from 410 nuclear medicine department/facility managers nationwide. Responses were projected to the universe of 6,985 short-term general hospitals, imaging centers and physician practices in the United States that have fixed nuclear medicine cameras as identified by IMV. 
For more information: www.imvinfo.com

Related Content

blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging| September 23, 2015
September 23, 2015 — New research de
Novation, Mo-99, NNSA 2015 meeting, reliable supplies, domestic production
News | Radiopharmaceuticals and Tracers| September 17, 2015
At the National Nuclear Security Administration’s (NNSA) 2015 Mo-99 Topical Meeting, Novation offered its support of...
PET, imaging agent, hidden blood clots, MGH, radiopharmaceutical probe, 64Cu-FBP8
News | Radiopharmaceuticals and Tracers| September 16, 2015
A novel radiopharmaceutical probe developed at Massachusetts General Hospital (MGH) has the potential of providing...
Zevacor, IBA, 70 MeV cyclotron, Cyclone 70P, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| September 11, 2015
Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon...
News | Radiopharmaceuticals and Tracers| September 11, 2015
Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore...
NorthStar Medical Radioisotopes, approval, routine production, Molybdenum-99, Mo-99, University of Missouri Research Reactor, MURR
News | Radiopharmaceuticals and Tracers| August 31, 2015
NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the...
Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
Medraysintell, nuclear medicine, World Market Report, radiopharmaceuticals
News | Nuclear Imaging| July 06, 2015
Medraysintell released its updated World Market Report and Directory on Nuclear Medicine, Edition 2015, in late June,...
nuclear medicine diagnostic market, North America, PET, SPECT, Mordor
News | Nuclear Imaging| June 29, 2015
The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for...
Siemens, MES contract, William Osler Health System, Ontario, Canada
News | Cardiac Imaging| June 26, 2015
Canadian hospital William Osler Health System (Osler), based in Ontario, has awarded Siemens Healthcare a Managed...
Overlay Init